Literature DB >> 415924

Proposals for quality control methods of bacterial vaccines for immunostimulation. III. Effect of BCG and C. parvum on in vivo Listeria clearance and tumor growth.

E J Ruitenberg, P A Steerenberg, L M van Noorle Jansen.   

Abstract

Two quality control methods for BCG and C. parvum are described. First, in vivo macrophage dependent-spleen clearance of Listeria monocytogenes in inbred B10LP mice. BCG and C. parvum were administered intravenously prior to listeria inoculation (a prophylactic model). Conditions for enhanced listeria clearance including dose, route and time interval were described for each vaccine. Next, a tumor model was developed: i.e. a fibrosarcoma, chemically induced by 20-methylcholanthrene in inbred Balb/c mice. Increase in footpad thickness was used as a criterion for tumor growth. Optimal dose, route and time interval were established both in prophylactic and therapeutic situations, including intratumoral application. Depending on the conditions chosen, both inhibition and enhancement of tumor growth were observed. General conclusions of these studies are: (a) both models yield information on the effect of bacterial vaccines for immunostimulation; (b) statements on the effectiveness of any product should be based on careful studies including all variables.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 415924

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  2 in total

1.  Effects of lactobacilli on parameters of non-specific resistance of mice.

Authors:  N Bloksma; H Ettekoven; F M Hofhuis; L van Noorle-Jansen; M J De Reuver; J G Kreeftenberg; J M Willers
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

2.  Experimental screening of BCG preparations produced for cancer immunotherapy: safety and immunostimulating and antitumor activity of four consecutively produced batches.

Authors:  W H de Jong; P A Steerenberg; J G Kreeftenberg; R H Tiesjema; W Kruizinga; L M van Noorle Jansen; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.